1-20 of 1408
nilotinib
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Paola Aimone, Alex Allepuz, Sara Quenet, Florence Hourcade-Potelleret, Sabine Hertle, Darintr Sosothikul
Journal: Blood
Blood (2019) 134 (23): 2036–2045.
https://doi.org/10.1182/blood.2019000069
Published: 2019
Includes: Supplemental data
Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3812.
https://doi.org/10.1182/blood-2019-131838
Published: 2019
Journal Articles

Metabolomics Profile of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Giovanni Caocci, MD, Martino Deidda, Antonio Noto, Christian Cadeddu, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa
Journal: Blood
Blood (2019) 134 (Supplement_1): 4144.
https://doi.org/10.1182/blood-2019-124323
Published: 2019
Journal Articles

Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial

Gabriele Gugliotta, MD PhD, Fausto Castagnetti, MD PhD, Massimo Breccia, MD, Luciano Levato, MD, Tamara Intermesoli, MD, Mariella D'adda, Marzia Salvucci, MD, Fabio Stagno, MD, Giovanna Rege Cambrin, MD PhD, Mario Tiribelli, Bruno Martino, MD, Monica Bocchia, Elena Trabacchi, MD, Francesco Cavazzini, MD, Ferdinando Porretto, Federica Sorà, MD, Giovanni Caocci, MD, Francesco Albano, MD, Giovanni Martinelli, MD, Simona Soverini, PhD, Robin Foà, MD, Fabrizio Pane, MD, Michele Cavo, Giuseppe Saglio, MD, Michele Baccarani, MD, Gianantonio Rosti, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4145.
https://doi.org/10.1182/blood-2019-126163
Published: 2019
Journal Articles

Prognostic Effects of Pretreatment Statuses at Diagnosis in Patients with Chronic Myeloid Leukemia: Results of the New Target Observational Study 1

Takaaki ONO, MD PhD, Naoto Takahashi, MD PhD, Masahiro Kizaki, MD, Tatsuya Kawaguchi, MD, Ritsuro Suzuki, MD PhD, Kazuhito Yamamoto, Kazunori Ohnishi, MD, Tomoki Naoe, MD PhD, Itaru Matsumura, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4149.
https://doi.org/10.1182/blood-2019-122092
Published: 2019
Journal Articles

R-Interferon Treatment before Imatinib Reverses the Negative Impact of e13a2 Transcript Type on Treatment Free Remission Duration after Tyrosine Kinase Inhibitors Discontinuation in Chronic Myeloid Leukemia Patients

Mariella D'Adda, MD, Mirko Farina, MD, Angela Passi, MD, Rosa Daffini, MD, Doriana Gramegna, MD, Elisa Cerqui, MD, Samantha Ferrari, MD, Chiara Bottelli, MD, Chiara Pagani, MD, Erika Borlenghi, MD, Diego Bertoli, PhD, Silvana Archetti, PhD, Mirella Marini, MD, Giuseppe Rossi
Journal: Blood
Blood (2019) 134 (Supplement_1): 4146.
https://doi.org/10.1182/blood-2019-125313
Published: 2019
Journal Articles

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Stuart L. Goldberg, MD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Scott Justin Keating, MSc, BSc, Hitesh Bhandari, Clara Chen, PhD BS, MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 4151.
https://doi.org/10.1182/blood-2019-128290
Published: 2019
Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 64.
https://doi.org/10.1182/blood-2019-128905
Published: 2019
Journal Articles

Activation of AKT/mTOR Pathway in Ph+ Acute Lymphoblastic Leukemia (ALL) Leads to Non-Mutational Resistance

Afsar Ali Mian, BSc, MPhil, PhD, Usva Zafar, BSc, Oliver Ottmann, Prof, MD, Martin Ruthardt, MD, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA
Journal: Blood
Blood (2019) 134 (Supplement_1): 2570.
https://doi.org/10.1182/blood-2019-130898
Published: 2019
Journal Articles

Preclinical Activity of the MPS1 Inhibitor S81694 in Acute Lymphoblastic Leukemia (ALL)

Anna Kaci, PhD, Emilie Adiceam, Melanie Dupont, Marine Garrido, Jeannig Berrou, Hanane Djamai, Andre Baruchel, Mike Burbridge, Claude Gardin, Herve Dombret, MD PhD, Thorsten Braun, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2631.
https://doi.org/10.1182/blood-2019-125641
Published: 2019
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Naranie Shanmuganathan, MBBS FRACP FRCPA, Andrew Grigg, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MBBS FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MD, Agnes S. M. Yong, MD PhD, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 2926.
https://doi.org/10.1182/blood-2019-125740
Published: 2019
Journal Articles

A 20-Year Review of Imatinib in Chronic Phase Chronic Myeloid Leukemia Patients after Failure with Interferon Therapy

Maria R Vazquez, Hagop M. Kantarjian, MD, Gautam M. Borthakur, MD, Susan O'Brien, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MD, Alessandra Ferrajoli, MD, Jorge E. Cortes, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Guillermo Garcia-Manero, MD, Sara E Dellasala, BS, Kathleen A Kehr, MD, Sherry A. Pierce, BSN, BA, Mary B. Rios, RN, Elias Jabbour, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2927.
https://doi.org/10.1182/blood-2019-132246
Published: 2019
Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Hugues De Lavallade, Sophie Jackson, BSc, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Sebastian Francis, MBChB, MRCP, Edward Belsham, FRCPath, MB, Paul Cahalin, MA MRCP FRCPath, Joanne Ewing, PhDBMBS BSc FRPATH, Jenny Byrne, MD PhD, Kate Rothwell, BA MB BChir, PhD, Sandra Hassan, MBBS, MRCP, FRCPath, MDRes), Srinivas Pillai, MBBS,MD MRCP, FRCPath, Priyanka Mehta, Anshu Garg, MBBS,MDMRCP,FRCPath, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Oliver Ottmann, Prof, MD, Deepti Radia, Patrick Harrington, MRCP, FRCPath, Rachel Greig, Nicholas Lea, PhD, Michael Thompson, Aytug Kizilors, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2935.
https://doi.org/10.1182/blood-2019-129825
Published: 2019
Journal Articles

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Stuart L. Goldberg, MD, Michael J. Mauro, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2929.
https://doi.org/10.1182/blood-2019-127959
Published: 2019
Journal Articles

Analyses of Predictors of Durable Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Frontline or Second-Line Nilotinib

Jerald P. Radich, MD, Andreas Hochhaus, MD, Francis J. Giles, MD FRCPI, FRCPath, David M. Ross, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Dong-Wook Kim, Rafik Fellague-Chebra, MD, Manu Sondhi, MD PhD, Ranjan Tiwari, MSc, Kaushal Mishra, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2932.
https://doi.org/10.1182/blood-2019-129393
Published: 2019
Journal Articles

Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis

Timothy P. Hughes, MDMBBS,FRACP,FRCPA, Giuseppe Saglio, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Dong-Wook Kim, Surapol Issaragrisil, MD, Philipp Le Coutre, MD, Gabriel Etienne, MD PhD, Carla Boquimpani, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Viviane Dubruille, MD, Ian W. Flinn, MD PhD, Slawomira Kyrcz-Krzemien, MD PhD, Ewa Medras, MD, Maria Zanichelli, MD, Israel Bendit, MD PhD, Manu Sondhi, MD PhD, Ksenia Titorenko, MS, Claire Nourry-Boulot, PhD, Paola Aimone, MD, Andreas Hochhaus, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2924.
https://doi.org/10.1182/blood-2019-128761
Published: 2019
Journal Articles

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Hannah Asghari, MD BS, Chetasi Talati, MD, Alexandra Achille, John J. Powers, BS, Eva Sahakian, PhD, Onyee Chan, MD, Dawne N Shelton, PhD, Leidy Isenalumhe, MD, Lisa Nodzon, PhD ARNP, AOCNP, Kendra L. Sweet, MD, Javier Pinilla Ibarz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3382.
https://doi.org/10.1182/blood-2019-131207
Published: 2019
Journal Articles

Dose Optimization in Elderly CML Patients Treated with Bosutinib after Intolerance or Failure of First-Line Tyrosine Kinase Inhibitors

Fausto Castagnetti, MD PhD, Gabriele Gugliotta, MD PhD, Monica Bocchia, Malgorzata Monika Trawinska, MD, Isabella Capodanno, MD, Massimiliano Bonifacio, MD, Giovanna Rege Cambrin, MD PhD, Monica Crugnola, MD, Gianni Binotto, MD, Chiara Elena, MD, Alessandro Lucchesi, MD, Micaela Bergamaschi, MD, Francesco Albano, MD, Luigiana Luciano, MD, Federica Sorà, MD, Francesca Lunghi, MD, Fabio Stagno, MD, Patrizia Pregno, Alessandra Iurlo, MD, Anna Rita Scortechini, MD, Michele Cedrone, MD, Raffaele Spadano, MD, Elena Trabacchi, MD, Monia Lunghi, MD, Giuseppina Spinosa, MD, Dario Ferrero, MD, Massimo Pini, MD, Davide Rapezzi, MD, Laura Nocilli, MD, Michele Cavo, Giuseppe Saglio, MD, Fabrizio Pane, MD, Michele Baccarani, MD, Gianantonio Rosti, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 496.
https://doi.org/10.1182/blood-2019-127514
Published: 2019
Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Franck E Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnès Guerci-Bresler, MD PhD, Aude Charbonnier, MD PhD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD PhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, MD PhD, Denis Guyotat, MD PhD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Eric Deconinck, MD PhD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Alexandre Deloire, CRA, Stephane Morisset, BioStat, Madeleine Etienne, CRA, Delphine Rea, MD, Stephanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 494.
https://doi.org/10.1182/blood-2019-123674
Published: 2019
Journal Articles

Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

Alessandra Trojani, Ester Pungolino, Giuseppe Rossi, Mariella D'adda, Luca Emanuele Bossi, Giacomo Baruzzo, Barbara Di Camillo, Alessandra Perego, Mauro Turrini, Chiara Elena, MD, Lorenza Maria Borin, Alessandra Iurlo, MD PhD, Simona Malato, Francesco Spina, Maria Luisa Latargia, Pierangelo Spedini, Salvatore Artale, Michela Anghilieri, Maria Cristina Carraro, Cristina Bucelli, Gabriella De Canal, Enrica Morra, Roberto Cairoli, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5034.
https://doi.org/10.1182/blood-2019-125595
Published: 2019